GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Optimind Pharma Corp (XCNQ:OMND) » Definitions » Net Income From Continuing Operations

Optimind Pharma (XCNQ:OMND) Net Income From Continuing Operations : C$-2.68 Mil (TTM As of Nov. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Optimind Pharma Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Optimind Pharma's net income from continuing operations for the three months ended in Nov. 2023 was C$-0.10 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Nov. 2023 was C$-2.68 Mil.

Optimind Pharma Net Income From Continuing Operations Historical Data

The historical data trend for Optimind Pharma's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Optimind Pharma Net Income From Continuing Operations Chart

Optimind Pharma Annual Data
Trend Feb22 Feb23
Net Income From Continuing Operations
- -3.08

Optimind Pharma Quarterly Data
Jun21 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
Net Income From Continuing Operations Get a 7-Day Free Trial -0.32 -1.98 -0.40 -0.18 -0.10

Optimind Pharma Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Nov. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Optimind Pharma (XCNQ:OMND) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Optimind Pharma Corp (XCNQ:OMND) » Definitions » Net Income From Continuing Operations
Comparable Companies
XCNQ:NLV TSXV:GENX XCNQ:AYUR XCNQ:PHRX XCNQ:J XCNQ:CRCC XCNQ:BCBC XCNQ:CVGR XCNQ:PBF TSXV:HMPG ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
3000 - 77 King Street West, TD Centre, North Tower, PO Box 95, Toronto, ON, CAN, M5K 1G8
Website
https://www.optimindpharma.com
Optimind Pharma Corp is an emerging provider of psychedelic therapies for the masses. It helps people suffering from PTSD, Anxiety, Depression, and other mental illnesses and disabilities by providing ketamine-assisted-treatment and other psychedelic-enhanced-psychotherapy modalities.

Optimind Pharma (XCNQ:OMND) Headlines

No Headlines